Women New to PrEP Showed Higher Uptake of Lenacapavir Than Women Switching From Other Options in Gilead Data
Gilead's early U.S. data suggest twice-yearly lenacapavir is attracting women who had not previously used PrEP, although the company analysis cannot establish effects on HIV rates.
Medical Daily ·